江苏恩华药业股份有限公司 2024年限制性股票激励计划 实施考核管理办法 2024年6月 -1- 前言 江苏恩华药业股份有限公司（以下简称"恩华药业"或"公司"）为了进一步建立、健全公 司长效激励机制，吸引和留住优秀人才，充分调动员工的积极性和创造力，提高员工的凝聚 力和公司竞争力，有效地将股东利益、公司利益和激励对象个人利益结合，促进公司长期、 持续、健康发展，公司拟对公司（含分公司及控股子公司，下同）董事、高级管理人员、中 层管理人员及核心骨干员工进行股权激励，制定了《江苏恩华药业股份有限公司2024年限制 性股票激励计划（草案）》（以下简称"激励计划"、"本次激励计划"）。 以上激励对象中，高级管理人员必须经公司董事会聘任。所有激励对象必须在公司授予 限制性股票时以及本次激励计划的考核期内与公司具有雇佣关系或劳务关系。 二、考核组织职责权限 1、董事会薪酬与考核委员会负责组织和审核考核工作。 为保证公司股权激励计划的顺利实施，现根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司股权激励管理办法》等有关法律、法规和规范性文件、以及《江苏 恩华药业股份有限公司章程》的相关规定，并结合公司的实际 ...

上市公司股权激励计划自查表 公司简称：恩华药业 股票代码：002262 独立财务顾问：上海荣正企业咨询服务(集团)股份有限公司 2 | 至下期；如激励对象包括董事和高管，应当披露激励对象行 | 使权益的绩效考核指标；披露激励对象行使权益的绩效考核 | | | | | | --- | --- | --- | --- | --- | --- | | 指标的，应充分披露所设定指标的科学性和合理性；公司同 | 时实行多期股权激励计划的，后期激励计划公司业绩指标如 | | | | | | 低于前期激励计划，应当充分说明原因及合理性 | （8）公司授予权益及激励对象行使权益的程序；当中，应 | | | | | | 明确上市公司不得授出限制性股票以及激励对象不得行使 | 是 | 权益的期间 | | | | | （9）股权激励计划所涉及的权益数量、行权价格的调整方 | 是 | 法和程序（例如实施利润分配、配股等方案时的调整方法） | | | | | （10）股权激励会计处理方法，限制性股票或股票期权公允 | 价值的确定方法，估值模型重要参数取值及其合理性，实施 | 是 | | | | | 股权激励应当计提费用及对上市公司经营 ...

江苏恩华药业股份有限公司 2024年限制性股票激励计划激励对象名单 一、 激励对象获授的限制性股票分配情况 注：上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 二、中层管理人员、核心骨干员工名单 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 解忠军 | 中层管理人员、核心骨干员工 | | 2 | 徐香龙 | 中层管理人员、核心骨干员工 | | 3 | 许向阳 | 中层管理人员、核心骨干员工 | | 4 | 万泽红 | 中层管理人员、核心骨干员工 | | 5 | 王卫兵 | 中层管理人员、核心骨干员工 | | 6 | 杜克文 | 中层管理人员、核心骨干员工 | | 7 | 成素巧 | 中层管理人员、核心骨干员工 | | 8 | 马丕林 | 中层管理人员、核心骨干员工 | | 9 | 刘雷 | 中层管理人员、核心骨干员工 | | 10 | 刘启新 | 中层管理人员、核心骨干员工 | | 11 | 邵敏 | 中层管理人员、核心骨干员工 | | 12 | 陈健 | 中层管理人员、核心骨干员工 | | 13 | 董达文 | 中层管理人员、核心骨干员工 | | ...

关于完成《公司章程修正案》备案登记手续的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：002262 证券简称：恩华药业 公告编号：2024-024 江苏恩华药业股份有限公司 2024年5月28日 根据江苏恩华药业股份有限公司（以下简称"公司"） 2023年度股东大会决议的相 关授权及要求，公司董事会已于2024年5月22日向登记机关申请办理《公司章程修正案》 的备案登记手续。2024年5月28日，公司收到徐州市政务服务管理办公室出具的《登记 通知书》，告知公司已完成对《公司章程修正案》的备案登记手续。 特此公告。 江苏恩华药业股份有限公司董事会 ...

1、2024年4月24日召开的2023年度股东大会审议通过了《2023年度利润分配预案》。公 司2023年度利润分配方案为：以2023年12月31日总股本1,007,588,092股为基数，向全体股东 每10股派发现金红利3.20元（含税），本次实际分配现金股利共计322,428,189.44元。不送红 股，亦不进行资本公积转增股本。本次利润分配方案实施后留存未分配利润4,490,590,954.54 元，结转以后年度进行分配。分配预案公布后至实施前，如公司总股本由于可转债转股、股 份回购、股权激励行权、再融资新增股份上市等原因发生变动，按照"现金分红比例不变"的 原则相应调整。 证券代码：002262 证券简称：恩华药业 公告编号：2024-022 江苏恩华药业股份有限公司 2023年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 公司声明：本次实施的分配方案与股东大会审议通过的分配方案及其调整原则一致，距 离股东大会审议通过利润分配方案的时间未超过两个月。 一、股东大会审议通过的利润分配方案等情况 2、 本次实施的权益分派方案与公司2 ...

北京市立方律师事务所 关于江苏恩华药业股份有限公司 北京市立方律师事务所 关于江苏恩华药业股份有限公司 2023 年度股东大会的 法律意见书 致：江苏恩华药业股份有限公司 根据《中华人民共和国证券法》 、《中华人民共和国公司法》(以下简称"《公司 法》")、《上市公司股东大会规则》(以下简称"《股东大会规则》")、《律师事务 所从事证券法律业务管理办法》(以下简称"《证券法律业务管理办法》") 等 相关法律、法规和规范性文件以及《江苏恩华药业股份有限公司公司章程》(以 下简称"《公司章程》") 的规定，北京市立方律师事务所 (以下简称"本所") 指 派律师出席江苏恩华药业股份有限公司 (以下简称"恩华药业")2023 年度股东 大会 (以下简称"本次股东大会")， 并出具本法律意见书。 2023 年度股东大会的 法律意见书 2024 年 4 月 对本法律意见书的出具，本所律师特作如下声明： 1、本所律师已经按照《股东大会规则》的要求对本次股东大会的真实性、 合 法性进行了核查和验证 (以下简称"查验") 并发表法律意见，本法律意见书中 不存在虚假记载、误导性陈述及重大遗漏。 2、本所律师仅对恩华药业本次股东大 ...

Financial Performance - The company's revenue for Q1 2024 reached ¥1,357,565,651.12, representing a 15.16% increase compared to ¥1,178,806,488.43 in the same period last year[3] - Net profit attributable to shareholders was ¥265,282,248.03, up 16.64% from ¥227,429,413.46 year-on-year[3] - Net profit for Q1 2024 was ¥264,638,776.41, up 17.5% from ¥225,173,396.19 in Q1 2023[15] - Operating profit for the quarter was ¥304,871,280.84, a rise of 16.6% from ¥261,579,559.01 in the same quarter last year[15] - The total comprehensive income for Q1 2024 was ¥264,638,776.41, compared to ¥225,173,396.19 in Q1 2023, reflecting a growth of 17.5%[15] Cash Flow - The net cash flow from operating activities decreased by 35.90%, amounting to ¥233,582,275.30 compared to ¥364,395,839.44 in the previous year[3] - The cash outflow from operating activities totaled CNY 1,232,818,489.41, an increase of 20.9% from CNY 1,019,601,827.61 in the previous period[17] - The cash inflow from sales of goods and services is CNY 1,437,966,302.56, an increase of 5.4% from CNY 1,364,465,949.94 in the previous period[17] - The cash outflow for purchasing goods and services is CNY 343,920,750.51, an increase of 15.2% compared to CNY 298,419,576.07 in the previous period[17] - The cash outflow for taxes paid is CNY 208,319,468.23, an increase of 32.6% from CNY 157,069,102.72 in the previous period[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,603,954,816.16, a 3.76% increase from ¥7,328,195,368.67 at the end of the previous year[3] - The total assets of Jiangsu Enhua Pharmaceutical Co., Ltd. reached CNY 7,603,954,816.16 at the end of the first quarter, an increase from CNY 7,328,195,368.67 at the beginning of the period[11] - The total liabilities of the company were CNY 929,208,374.37, a slight increase from CNY 918,087,703.29, reflecting a growth of approximately 1.2%[12] - The total current liabilities amounted to CNY 823,477,079.03, slightly up from CNY 814,027,830.97, showing an increase of approximately 1.8%[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,628, with the largest shareholder holding 31.77% of the shares[8] - The equity attributable to shareholders of the parent company increased to ¥6,699,423,735.51, up from ¥6,434,141,487.48, marking a growth of 4.1%[13] - The total equity attributable to shareholders increased by 4.12%, reaching ¥6,699,423,735.51 compared to ¥6,434,141,487.48 at the end of the previous year[3] Research and Development - R&D expenses increased by 30.77%, indicating a significant rise in investment in research and development activities[7] - Research and development expenses increased to ¥143,419,925.68, representing a 30.8% rise from ¥109,676,566.12 in the previous year[14] Investment Income - The company recorded a total of ¥6,725,654.77 in investment income from financial products, reflecting effective cash management strategies[5] - The cash inflow from investment income is CNY 6,725,654.77, a decrease of 40.5% from CNY 11,360,194.34 in the previous period[18] Inventory and Receivables - Trade receivables increased to CNY 1,117,797,379.75, up from CNY 1,034,736,344.97, indicating a growth of about 8%[11] - The inventory decreased to CNY 578,955,190.48 from CNY 628,637,457.97, representing a decline of approximately 7.9%[11]

Financial Performance - The company's operating revenue for 2023 reached ¥5,041,504,467.27, representing a 17.28% increase compared to ¥4,298,513,062.14 in 2022[13]. - Net profit attributable to shareholders for 2023 was ¥1,036,918,058.61, up 15.12% from ¥900,926,029.55 in 2022[13]. - The net profit after deducting non-recurring gains and losses was ¥1,013,075,096.44, reflecting a 16.11% increase from ¥872,759,321.20 in 2022[13]. - The net cash flow from operating activities for 2023 was ¥1,008,300,046.42, which is a 17.10% increase from ¥861,023,149.69 in 2022[13]. - Basic earnings per share for 2023 were ¥1.03, a 15.73% increase compared to ¥0.89 in 2022[13]. - Total assets at the end of 2023 amounted to ¥7,328,195,368.67, marking a 13.07% increase from ¥6,481,745,574.76 at the end of 2022[13]. - The net assets attributable to shareholders increased by 14.46% to ¥6,434,141,487.48 from ¥5,622,248,624.37 in 2022[13]. - The company reported a weighted average return on equity of 17.28% for 2023, slightly up from 17.20% in 2022[13]. - Operating profit for the year was ¥1,182,344,167.98, an increase of 17.83% compared to the previous year[40]. - The total profit amounted to ¥1,168,644,097.61, reflecting an 18.06% growth year-on-year[40]. Dividend Distribution - The company plans to distribute a cash dividend of 3.20 CNY per 10 shares to all shareholders, based on a total of 1,007,588,092 shares[2]. - The company has not proposed any stock bonus or capital increase from reserves in the profit distribution plan[2]. - The cash dividend distribution plan proposes a cash dividend of CNY 3.20 per 10 shares, totaling CNY 322,428,189.44, which accounts for 100% of the distributable profit[140]. - The total distributable profit available for shareholders is CNY 4,813,019,143.98, after accounting for the previous year's dividend distribution[140]. - The retained undistributed profit after the dividend distribution will be CNY 4,490,590,954.54 for future allocation[140]. Research and Development - The company increased R&D investment to 614 million CNY, a growth of 23.92% year-on-year, with over 70 ongoing research projects[34]. - The company has 20 innovative drug projects and 41 generic drug projects currently under development, with 14 projects undergoing consistency evaluation[26]. - The company applied for 78 invention patents and 42 PCT patent applications during the reporting period, receiving 28 authorized invention patents[34]. - The company has completed Phase I clinical trials for several antidepressant drugs, with plans to initiate Phase II trials in 2024 for some of them[45]. - The company is preparing to submit IND applications for several new drugs in 2024[45]. - The company has a robust pipeline with 14 consistency evaluation projects and several products in preclinical research stages[44]. Market Position and Strategy - The pharmaceutical industry in China is experiencing rapid growth, becoming the second-largest drug consumption market globally, following the United States[21]. - The company is positioned in the central nervous system drug sector, which is critical for addressing mental health issues and neurodegenerative diseases[23]. - The company is a key producer and seller of central nervous system drugs in China, with a comprehensive product line and a strong competitive edge in the industry[26]. - The company anticipates ongoing opportunities in the pharmaceutical industry due to increasing health awareness and demand for high-quality medical services[22]. - The company is committed to leveraging new technologies and biopharmaceutical advancements to capture opportunities in the evolving healthcare landscape[23]. Regulatory and Compliance - The company has established a quality management system in accordance with GMP requirements, achieving recognition as an excellent quality management enterprise in Jiangsu Province[60]. - The company has maintained effective internal controls as per the internal control audit report dated March 30, 2024[147]. - The company strictly adhered to corporate governance regulations, ensuring no violations related to fund occupation or investor rights[148]. - The company has implemented a long-term mechanism to prevent the controlling shareholder from occupying company funds, ensuring the protection of shareholder rights[112]. - The company has established a complete procurement, production, sales, and R&D system, demonstrating its independent operational capability without reliance on the controlling shareholder[112]. Environmental Responsibility - Jiangsu Enhua's environmental management system is certified under ISO 14001, demonstrating commitment to environmental standards[151]. - The company achieved stable compliance in wastewater discharge, with COD levels at 7.55 and ammonia nitrogen at 0.55, well within regulatory limits[153]. - The company invested CNY 3 million in environmental protection measures, enhancing the efficiency of the waste gas collection system, achieving over 95% treatment efficiency[155]. - The company received a national special subsidy of CNY 1.33 million for the soil pollution source control project, which had a total investment of CNY 4 million[158]. - The company was awarded the "Green Factory" honor in Jiangsu Province in 2023, and its subsidiary received the title of "Environmental Protection Demonstration Enterprise" in Xuzhou[158]. Corporate Governance - The company has a strong governance structure with a board of directors, supervisory board, and independent directors ensuring oversight and accountability[116]. - The company has established a performance evaluation and incentive mechanism for its directors and managers, promoting transparency and accountability[110]. - The company has committed to social responsibility by participating in charitable activities and donating medicines and funds to local poverty alleviation efforts[111]. - The company actively engages with investors through various communication channels, enhancing transparency and investor relations[111]. - The company has a clear financial decision-making process, with independent bank accounts and tax registrations, ensuring compliance with legal requirements[113]. Future Outlook - The company aims for a 15% growth in business revenue, total profit, and net profit for 2024 compared to the audited figures for 2023[99]. - The company plans to accelerate the launch of 8 innovative drugs in clinical trials in 2024, including NH600001 and NH300231[99]. - The company expects to approve 4 generic drugs for market launch in 2024, including Pregabalin capsules and Alfentanil injection[99]. - The company plans to deepen its international strategy by accelerating international certification and registration of its products, while also seeking partnerships with foreign pharmaceutical companies[103]. - The company is committed to internal growth while considering external expansion through mergers and acquisitions to achieve market share growth[103].

江苏恩华药业股份有限公司 关于审计委员会对会计师事务所 2023 年度履职情况监督报告 根据《中华人民共和国公司法》《上市公司治理准则》《国有企业、上市公司选聘会计师事 务所管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 和江苏恩华药业股份有限公司（以下简称"恩华药业"或"公司"）的《公司章程》等有关规定和 要求，公司审计委员会本着勤勉尽责的原则，恪尽职守、认真履职，对立信会计师事务所（特 殊普通合伙）（以下简称"立信所"）2023 年度履职情况进行监督。具体情况如下： 一、2023 年年审会计师事务所基本情况 在执行审计工作的过程中，立信所就会计师事务所和相关审计人员的独立性、注册会计师 与财务报表审计相关的责任、计划的审计范围和时间安排、审计过程中遇到的重大事项、关键 审计事项、审计报告类型等与公司管理层和治理层进行了沟通。 （一）会计师事务所基本情况 三、审计委员会对会计师事务所的履职监督情况 根据公司《董事会审计委员会议事规则》等有关规定，审计委员会对立信所履行监督职责 的情况如下: （一）董事会审计委员会对立信所专业资质、业务能力、诚信状况、独立性、过往审计工 作 ...

证券代码：002262 证券简称：恩华药业 公告编号：2023-041 注册分类：化学药品 江苏恩华药业股份有限公司 关于阿普唑仑片通过仿制药一致性评价的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 江苏恩华药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的关于阿普唑仑片的《药品补充申请批准通知书》，批准该药 品通过仿制药质量和疗效一致性评价（以下简称"一致性评价"）。现将相关情况公告如下： 一、《药品补充申请批准通知书》主要内容及产品基本信息 药品通用名称：阿普唑仑片 剂型：片剂 规格：0.4mg 申请内容：一致性评价申请 申请人：江苏恩华药业股份有限公司 受理号：CYHB2250637 通知书编号：2023B05895 审批结论： 根据《中华人民共和国药品管理法》《国务院关于改革药品医疗器械审评审批制度的意 见》（国发[2015] 44号）和《关于仿制药质量和疗效一致性评价工作有关事项的公告》 （2017年第100号）的规定，经审查，本品通过仿制药质量和疗效一致性评价。 二、药品其他情况 阿普唑仑片主 ...